Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Pcsk-9 Inhibition on PET Coronary Flow Reserve in Patients at High Cardiovascular Risk (EMPOWER Study)

NCT05152888 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT05152888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05152888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Pcsk-9 Inhibition on PET Coronary Flow Reserve in Patients at High Cardiovascular Risk (EMPOWER Study)
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
March 3, 2022
Completion date
December 31, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stable coronary disease